Treatment coverage for schistosomiasis in Guinea

Guinea: Treatment coverage for schistosomiasis was 48.0% in 2024. ▲ Rising

Latest (2024)
48.0%
Change on year
up 9.8%
World rank
21st
of 45 countries
All-time high
48.0%
in 2024
All-time low
25.8%
in 2020
Years of data
9
2012–2024

Treatment coverage for schistosomiasis in Guinea, 2012–2024

010203040502012201820242012: 33.5 %2016: 31.2 %2017: 42.7 %2018: 47.1 %2020: 25.8 %2021: 45.4 %2022: 42.1 %2023: 43.7 %2024: 48 %

Source: World Health Organization (2025) – with minor processing by Our World in Data. Measured in %.

Analysis

Guinea recorded 48.0% for treatment coverage for schistosomiasis in 2024. That is the highest value across all 9 years on record.

The figure is up 9.8% on the previous year and up 42.9% over ten years.

Over the whole period, treatment coverage for schistosomiasis in Guinea peaked at 48.0% in 2024 and was at its lowest, 25.8%, in 2020.

Guinea ranks 21st of 45 countries on this measure, in the middle of the range.

Treatment coverage for schistosomiasis in Guinea, year by year

Annual values for Treatment coverage for schistosomiasis in Guinea, 2012 to 2024.
Year % Change
2012 33.5%
2016 31.2% -7.0%
2017 42.7% +37.0%
2018 47.1% +10.1%
2020 25.8% -45.2%
2021 45.4% +75.7%
2022 42.1% -7.2%
2023 43.7% +3.7%
2024 48.0% +9.8%

Guinea compared with similar countries

  • Guinea's 48.0% is above the median for Sub-Saharan Africa, which is 42.8%, 1.1× the median. (37 countries reporting)
  • Guinea's 48.0% is below the median for lower middle income countries, which is 51.6%, 93% of the median. (20 countries reporting)

Averages by decade

DecadeAverage LowestHighest Years
2010s 38.6% 31.2% 47.1% 4
2020s 41.0% 25.8% 48.0% 5

Countries ranked near Guinea

  1. 18 Eswatini 53.5% compare
  2. 19 Nigeria 49.6% compare
  3. 20 Angola 48.4% compare
  4. 22 Liberia 47.4% compare
  5. 23 Ethiopia 46.8% compare
  6. 24 Sao Tome and Principe 42.8% compare

See the full ranking of 45 places →

More reference data data for Guinea

All data for Guinea →

Frequently asked questions

What is treatment coverage for schistosomiasis in Guinea?
Treatment coverage for schistosomiasis in Guinea was 48.0% in 2024, according to World Health Organization (2025) – with minor processing by Our World in Data.
What is the highest treatment coverage for schistosomiasis recorded in Guinea?
The highest recorded value was 48.0% in 2024.
What is the lowest treatment coverage for schistosomiasis recorded in Guinea?
The lowest recorded value was 25.8% in 2020.
How does Guinea rank for treatment coverage for schistosomiasis?
Guinea ranks 21st out of 45 countries with data for 2024.
Is treatment coverage for schistosomiasis rising or falling in Guinea?
Over the last ten years it is up 42.9%. The long-run trend across the full record is rising.
Where does this Guinea data come from?
The figures come from World Health Organization (2025) – with minor processing by Our World in Data, published as part of Treatment coverage for schistosomiasis. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 9 observations, free to reuse under CC BY 4.0 (Our World in Data).

Share, cite or embed this page

Cite this page

Treatment coverage for schistosomiasis in Guinea. Statizoid, drawing on World Health Organization (2025) – with minor processing by Our World in Data. Retrieved 24 September 2026, from https://reference.statizoid.com/stat/schistosomiasis-treatment-coverage/guinea/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (Our World in Data); please keep the attribution.

<a href="https://reference.statizoid.com/stat/schistosomiasis-treatment-coverage/guinea/">Treatment coverage for schistosomiasis in Guinea</a> — Statizoid

About this data

Indicator
Treatment coverage for schistosomiasis
Unit
%
Source
World Health Organization (2025) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
45 places, 573 data points, 2006–2024
Last refreshed

Drug coverage out of estimated population who require it.